A FORMULATION DISPLAYING ANTI-CARCINOGENIC EFFECT BY SUPPRESSING NESTIN EXPRESSION
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Nestin Interleukin-6 Cancer

description: <strong>Field of Invention</strong> The present invention herewith discloses a formulation developed to display anti-carcinogenic effect by suppressing nestin expression. <strong>Background of the Related Technology</strong> At present the drugs used for treatment of cancer are called “anti-cancer” drugs. The objective of the chemotherapy may vary with the type of the cancer under treatment. Main objective is to treat the cancer. Cancer is deemed to be treated once all traces of cancer cells are removed. Controlling cancer is accepted to be the process, where the spreading of cancer in general is prevented and its growth is slowed, and thus the cancer is put under control. Its main objective is to eliminate the symptoms developed with cancer. Certain chemotherapy treatments mainly concentrate on eliminating or reducing pain and similar symptoms, to improve the life quality of the patient. It may not be possible to get the desired benefit from the chemotherapy medication all the time. If it is not possible to destroy the cancer tumors by treatment or if it is too late in treatment, the cancer cells may spread to the whole body by blood vessels or lymphatic system. This will lead to a condition called metastasis. In state of art technology, invention no “EP1615638B1", with title “Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy” and under classification number “A61K 31/4245 “discloses (Formula (I)); Derivatives of the heterocyclic compound known as 7-nitro-benzofurazan or 7-nitro-2,1,3-benzoxadiazole, of the general formula (I) are proposed as agents having a strong inhibiting activity towards members of the glutathione S-transferase (GST) superfamily that are hyperexpressed in cancer cells, and make them particularly resistant to many stress factors. These compounds are useful in the production of pharmaceutical drugs to be used in anticancer therapy, and may be employed either alone or in combination with other chemotherapeutic agents. The invention also concerns preparations for anticancer treatment that also include as active ingredient at least one of the derivatives of formula (I), optionally in combination with other chemotherapeutic agents. Again invention no “EP1560832B1”, with title “Pyrimido 4,5-d pyrimidine derivatives with anticancer activity” and under classification number “C07D 487/04 “discloses novel pyrimido compounds of the formula (I) and their pharmaceutically acceptable salts and their use in preparation of medicament for treatment and fighting against cancer. Again invention no “EP1689724B1", with title “Quinazolinone compounds as anticancer agents” and under classification number “C07D 239/90 “discloses novel quinazolinone compounds, their pharmaceutically acceptable salts, and pro-drugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent and also the methods of using the novel quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended to display anti-carcinogenic effect by suppressing nestin expression. <strong>Objective of the Invention</strong> To overcome the disadvantages experienced in state of art technology; One objective of the invention is to suppress nestin expression. One other objective of the invention is to suppress interleukin 6 expression. The present invention which is aimed to achieve the above-mentioned advantages, is intended to display anti-carcinogenic effect by suppressing nestin expression and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present invention herewith discloses a formulation developed to display anti-carcinogenic effect by suppressing nestin expression. Referred formulation suppresses nestin expression and suppresses interleukin 6 expression. The formulation of the invention presented herewith contains; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside . The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 20-80% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, 80-20% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time discloses using the above-referred formulation intended to display anti-carcinogenic effect by suppressing nestin expression and manufacturing it for such purpose. <strong>CLAIMS</strong> A formulation intended to display anti-carcinogenic effect by suppressing nestin expression and which consists of combining the components selected from the group; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside in a single form or in combinations thereof. The formulation of Claim 1 which is characterized by containing 20-80% of 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione by weight. The formulation of Claim 1 which is characterized by containing 80-20% of (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 1H-cyclopenta[a]phenylanthroyl-4-yl]oxy]-6-(dimethoxyethyl)oxane-3-yl]oxy-8-(dihydroxyethyl)oxane-3,5,7-trione, (3β,10β)-12,20-hexahydroxydamar-20-ene-4-caffeoyl 7-O-β-D-glucopyranosyl-β-D-trihydroxypyranoside from any one as given in Claims 2-3 in manufacturing the formulation intended to display anti-carcinogenic effect by suppressing nestin expression. <strong>SUMMARY</strong> <strong>A FORMULATION DISPLAYING ANTI-CARCINOGENIC EFFECT BY SUPPRESSING NESTIN EXPRESSION</strong> The present invention herewith discloses a formulation developed to display anti-carcinogenic effect by suppressing nestin expression. Referred formulation suppresses nestin expression and suppresses interleukin 6 expression